AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 151 min read$REGN

REGN Upgraded by UBS -- Price Target Raised to $978

UBS upgraded Regeneron Pharmaceuticals (REGN) to 'Buy' with a $978 price target, up 48.18% from $660. GuruFocus values REGN at $925.48, suggesting it's 14.0% undervalued. The company has a GF Score of 87/100, strong financials, and a market cap of $81.99B. Analysts cite growth potential and resilience in its products, like Eylea and Dupixent.

Original reporting
gurufocus.com
Published Oct 15, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 10:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$REGN
Bullish
high confidence
Mentioned
$REGN
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$REGNBullishMed
01

Why it matters

Analyst upgrade and higher target are likely to attract new buying, though recent insider sales and weak momentum suggest caution.

02

Market read

The upgrade provides a fresh catalyst for REGN, potentially influencing biotech ETFs and related stocks.

03

What to watch

Insider selling activity and lower momentum rank could temper the rally.

Relevance 7/10Novelty 8/10Timing: immediate today

Background

Regeneron is a large-cap biotech with flagship products Eylea and Dupixent. The upgrade follows a price target jump from $660 to $978.

Company-level read

Ticker impact

$REGNBullishHigh confidence
Context

UBS upgraded Regeneron to Buy and raised the price target to $978, a fresh analyst action affecting the stock.

Expected impact

likely upward pressure as the market prices in the higher target.

Evidence & confidence

The upgrade and sizable target increase signal improved outlook, prompting buying interest.

Market effects

Sector

Biotech sector may see modest lift from a leading name's upgrade.

Regional

US biotech stocks could benefit in the near term.

Global

Limited to investors tracking US biotech equities.

Counterpoint

What could challenge this read

The upgrade may be premature if upcoming trial data disappoints.

Key entities

  • company
    Regeneron Pharmaceuticals

    US-listed biotech (ticker REGN) receiving a UBS upgrade.

  • analyst_firm
    UBS

    Issued the Buy rating and new price target.

Read at source← All news

StoryUBS upgrades Regeneron to Buy and raises price target to $978

Related articles

OCT 14
$REGNMed

UBS Upgrades Regeneron Pharmaceuticals (REGN) on Next-Gen Dupixe

UBS upgraded Regeneron Pharmaceuticals (REGN) to Buy, citing undervaluation and a strong pipeline of next-gen Dupixent candidates. The firm set a $978 price target, implying 30% upside from the recent close of $778.36. Regeneron's GF Value is $923.58, suggesting 15.7% undervaluation. The company's GF Score is 87/100, reflecting robust financial health and profitability. Insiders have sold $12.9M in shares over the past year, while institutional guru ownership remains high.

gurufocus.com2 min
OCT 13
$REGNMedAI 9/10

Regeneron reports 84-week Phase III data for Pasatru in adult FOP

Regeneron Pharmaceuticals reported 84-week Phase III trial data for Pasatru in adults with fibrodysplasia ossificans progressiva (FOP). The trial showed Pasatru prevented new heterotopic ossification lesions and reduced flare-ups compared to placebo. Safety data remained consistent, with no deaths reported. Regulatory submissions are planned in several countries, including Japan.

finance.yahoo.com2 min
OCT 13
$REGNMed

Regeneron presents new long-term data for Pasatru

Regeneron Pharmaceuticals (Nasdaq: REGN) reported 84-week Phase III trial results for Pasatru (garetosmab-grts) in treating fibrodysplasia ossificans progressiva (FOP). The data showed sustained efficacy in stopping new bone growth and reducing flare-ups. REGN shares closed up 2.2% at $762.81 after the announcement. The findings were presented at the ASBMR Annual Meeting.

thepharmaletter.com3 min